de Jesus et al. Pediatric Rheumatology 2015, 13(Suppl 1):O35
http://www.ped-rheum.com/content/13/S1/O35

PEDIATRIC
RHEUMATOLOGY

ORAL PRESENTATION Open Access

Stratification of patients with autoinflammatory phenotypes by interferon (IFN) score suggests a new group of IFN mediated autoinflammatory diseases with overlapping clinical phenotypes

A Almeida de Jesus[1*], Z Deng[2], S Brooks[2], H Kim[1], G Montealegre[1], D Chapelle[1], Y Liu[2], B Marrero[1], L Malle[1], M O'Brien[1], W Goodspeed[1], Y Huang[1], P Hashkes[3], G Nasrullayeva[4], MT Terreri[5], C Silva[6], B Arabshahi[7], K O'Neill[8], M Punaro[9], L Moorthy[10], A Reinhardt[11], V Lilleby[12], J Niemela[13], S Rosenzweig[13], T Fleisher[13], R Goldbach-Mansky[1,13]

From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
Dresden, Germany. 30 September - 3 October 2015

Background

We have identified mutations in proteasome components as the cause of CANDLE syndrome and in *TMEM173/STING* as the cause for a severe vasculopathy and lung disease, SAVI. CANDLE and SAVI patients do not respond to IL-1 inhibition and consistently demonstrate marked up-regulation of IFN-inducible genes. Our data suggest innate immune dysregulation caused by chronic Type I IFN signaling in both conditions.

Objective

We hypothesize that the presence of IFN signature may identify patients with autoinflammatory disease (AID) who have genetic mutations in other IFN regulating genes.

Methods

To identify patients with IFN signatures, RNA sequencing (RNA-seq) from whole blood RNA was performed using HiSeq 2000 Illumina® platform. Heatmaps with 64 IFN response genes were assessed. Whole exome sequencing (WES) was performed from whole blood DNA.

Results

We identified 19 patients with marked upregulation of IFN inducible genes. WES was performed in 14 patients and parents (trios) and in 5 individual patients. Of the probands, 9/19 were female, 8/19 were Caucasian, 3 Asian, 2 Hispanic, 2 Norwegian and 4 had other ethnicities. All patients presented with immunodysregulatory phenotypes with clinical similarities to the previously described interferonopathies, including skin vasculitis/vasculopathy (9/19), panniculitis (12/19), myositis (5/19) and basal ganglion calcifications (5/19), but had no genetic diagnosis prior to NIH evaluation. The bioinformatics variant annotation, analysis and filtering workflow successfully identified mutations in IFN-regulating genes in 7 of the 19 probands. In one patient, we found a disease causing *de novo* and somatic mutation in *TREX1*. This patient also presented with an in-frame deletion in *DHX9* inherited from her mother and a missense mutation in *MAVS* inherited from her father. In one patient, we identified a *de novo* mutation in *DHX9* and this patient is also a compound heterozygous for mutations in *IFIH1/MDA5*. In a third patient, we found a missense mutation in *TREX1* inherited from the mother and a heterozygous variant in *MB21D1* (gene encoding cGAS) inherited from the father. A fourth patient with a clinical phenotype of CANDLE had two novel compound heterozygous mutations in *PSMG2*. Additionally, a male patient with lupus-like clinical and laboratory findings was found to have an X-linked mutation in *TREX2* gene. All mutations described were confirmed by Sanger sequencing.

[1]National Institutes of Health, Translational Autoinflammatory Diseases Section, Bethesda, USA
Full list of author information is available at the end of the article

BioMed Central

© 2015 de Jesus et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Conclusion

RNA-seq can be a tool for the identification of patients with an IFN signature and guide the search for disease causing variants in IFN-regulating genes by WES. However, disease causality of these mutations needs to be assessed in functional assays. Moreover the identification of patients with a type I interferon signature and a set of clinical features that are not seen in IL-1- mediated-AIDs allow stratification of a subset of AIDs that are typically "poor IL-1 responsive". Whether the IFN signature identifies a subset of patients that respond to the blockade of Type I IFN signaling needs to be further validated.

Authors' details
[1]National Institutes of Health, Translational Autoinflammatory Diseases Section, Bethesda, USA. [2]National Institutes of Health, NIAMS, Bethesda, USA. [3]Hebrew University School of Medicine, Jerusalem, Israel. [4]Azerbaijan Medical University, Department of Immunology, Baku, Azerbaijan. [5]Federal University of Sao Paulo, Sao Paulo, Brazil. [6]University of Sao Paulo, Sao Paulo, Brazil. [7]Inova Fairfax Hospital, Fairfax, USA. [8]Riley Children's Hospital, Indianapolis, USA. [9]Children's Medical Center Dallas, Dallas, USA. [10]Robert Wood Johnson University Hospital, New Brunswick, USA. [11]University of Nebraska Medical Center, Omaha, USA. [12]Rikshospitalet University Hospital, Oslo, Norway. [13]National Institutes of Health, Department of Laboratory Medicine, Bethesda, USA.

Published: 28 September 2015

doi:10.1186/1546-0096-13-S1-O35
Cite this article as: de Jesus *et al.*: Stratification of patients with autoinflammatory phenotypes by interferon (IFN) score suggests a new group of IFN mediated autoinflammatory diseases with overlapping clinical phenotypes. *Pediatric Rheumatology* 2015 **13**(Suppl 1):O35.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit